MUNICH, Germany, Aug. 22, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage precision psychiatry biopharma company, pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today the appointment of Dr. Maximilian Doebler, previous Head of Business Development & Licensing of HMNC Brain Health, as Chief Business Officer.
MUNICH, Germany, June 08, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), together with Develco pharma, today announced the dosing of the first patient in their second Phase 2 trial with oral prolonged-release Ketamine (KET01) for Treatment-Resistant Depression.
MUNICH, Germany, April 11, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a global precision psychiatry biopharma company, pioneering the development of personalized therapies...
HMNC Brain Health and Develco Pharma are forging ahead with development of oral prolonged-release ketamine after seeing a “positive trend” in treatment-resistant depression, with a midphase study slated to start in the second quarter.
Appointment accelerates Company’s development roadmap in targeted therapies for neuropsychiatric disorders The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry in...